Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

IVIG-PEG

Plasma-derived product · developed by Grifols Therapeutics LLC

Phase 3 Most advanced trial (none active)
GRFS Developer
1 Registered trials

What is IVIG-PEG?

IVIG-PEG is named in the trial registry as a treatment studied in primary immunodeficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Plasma-derived product
Therapy area
Immunology
Developer
Grifols Therapeutics LLC (GRFS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04561115 Phase 3 Primary Immunodeficiency Completed GRFS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Primary Immunodeficiency

More from Grifols Therapeutics LLC

albumin human, USP FDA approved Antithrombin III FDA approved factor VIII / von Willebrand factor FDA approved Alpha-1 Phase 3 C19-IG Phase 3 Fibrin Sealant Grifols Phase 3 GRF312 Phase 2 Human Plasma-Derived Fibrinogen Concentrate Phase 1/2 plasma-derived FVIII/VWF concentrate Phase 4

Follow GRFS, the company behind IVIG-PEG

See GRFS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GRFS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.